share_log

Aditxt | 8-K/A: Current report (Amendment)

Aditxt | 8-K/A: Current report (Amendment)

Aditxt | 8-K/A:重大事件(修正)
美股SEC公告 ·  2024/11/21 13:21

Moomoo AI 已提取核心訊息

Appili Therapeutics shareholders have overwhelmingly approved the proposed acquisition by Aditxt's subsidiary Adivir. The transaction deadline has been extended from November 19 to December 15, 2024, with Adivir agreeing to pay Appili a $115,000 waiver fee for the delay.Under the amended agreement, Appili shareholders will receive 0.0000686251 Aditxt shares and US$0.0467 cash for each Appili share, valuing the deal at approximately US$0.04673 per share. The transaction requires Aditxt to raise at least US$20 million in financing and repay minimum 50% of Appili's senior secured debt at closing, with remaining debt to be repaid by December 31, 2024.The company's financial position remains challenging with a $2.3 million loss for the six months ended September 30, 2024. Long-term debt totaled $10.4 million, including restructured loans from Long Zone Holdings due December 31, 2024, and bridge loans from Bloom Burton. The company continues to operate under going concern uncertainty pending transaction completion.
Appili Therapeutics shareholders have overwhelmingly approved the proposed acquisition by Aditxt's subsidiary Adivir. The transaction deadline has been extended from November 19 to December 15, 2024, with Adivir agreeing to pay Appili a $115,000 waiver fee for the delay.Under the amended agreement, Appili shareholders will receive 0.0000686251 Aditxt shares and US$0.0467 cash for each Appili share, valuing the deal at approximately US$0.04673 per share. The transaction requires Aditxt to raise at least US$20 million in financing and repay minimum 50% of Appili's senior secured debt at closing, with remaining debt to be repaid by December 31, 2024.The company's financial position remains challenging with a $2.3 million loss for the six months ended September 30, 2024. Long-term debt totaled $10.4 million, including restructured loans from Long Zone Holdings due December 31, 2024, and bridge loans from Bloom Burton. The company continues to operate under going concern uncertainty pending transaction completion.
Appili Therapeutics的股東已壓倒性地批准了Aditxt子公司Adivir的收購提議。交易截止日期已從2024年11月19日延長至2024年12月15日,Adivir同意支付Appili 115,000美元的豁免費以彌補延誤。根據修訂後的協議,Appili股東將每股獲得0.0000686251股Aditxt股票和0.0467美元現金,交易總值約爲每股0.04673美元。該交易要求Aditxt至少籌集2000萬美元融資,並在交易完成時償還Appili至少50%的高級擔保債務,其餘債務需在2024年12月31日前償還。公司的財務狀況仍然面臨挑戰,截至2024年9月30日的六個月內損失達到230萬美元。長期債務總額爲1040萬美元,包括到期日爲2024年12月31日的Long Zone Holdings重組貸款和來自Bloom Burton的橋接貸款。公司在交易完成前繼續在持續經營不確定性的情況下運營。
Appili Therapeutics的股東已壓倒性地批准了Aditxt子公司Adivir的收購提議。交易截止日期已從2024年11月19日延長至2024年12月15日,Adivir同意支付Appili 115,000美元的豁免費以彌補延誤。根據修訂後的協議,Appili股東將每股獲得0.0000686251股Aditxt股票和0.0467美元現金,交易總值約爲每股0.04673美元。該交易要求Aditxt至少籌集2000萬美元融資,並在交易完成時償還Appili至少50%的高級擔保債務,其餘債務需在2024年12月31日前償還。公司的財務狀況仍然面臨挑戰,截至2024年9月30日的六個月內損失達到230萬美元。長期債務總額爲1040萬美元,包括到期日爲2024年12月31日的Long Zone Holdings重組貸款和來自Bloom Burton的橋接貸款。公司在交易完成前繼續在持續經營不確定性的情況下運營。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息